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A B S T R A C T
Low-grade inflammation is a risk factor for depression, psychosis and other major psychiatric disorders. It is
associated with poor response to antidepressant and antipsychotics, and could potentially be a treatment target.
However, there is limited data on the prevalence of low-grade inflammation in major psychiatric disorders, and
on the characteristics of patients who show evidence of inflammation. We examined the prevalence of low-grade
inflammation and associated socio-demographic and clinical factors in acute psychiatric inpatients.
An anonymised search of the electronic patient records of Cambridgeshire and Peterborough NHS Foundation
Trust was used to identify patients aged 18–65 years who were hospitalised between 2013 and 2016 (inclusive).
We excluded patients on antibiotics or oral steroids, or with missing data. Inflammation was defined using serum
C-reactive protein (> 3mg/L) or total white cell count (> 9.4×109/L) as measured within 14 days of admis-
sion.
Out of all 599 admissions, the prevalence of inflammation (serum CRP>3mg/L) in the ICD-10 diagnostic
groups of psychotic disorders (F20–29), mood disorders (F30–39), neurotic disorders (F40–48) and personality
disorders (F60–69) was 32%, 21%, 22% and 42%, respectively. In multivariable analyses, low-grade in-
flammation was associated with older age, black ethnicity, being single, self-harm, diagnoses of schizophrenia,
bipolar disorder, current treatments with antidepressants, benzodiazepines, and with current treatment for
medical comorbidities.
A notable proportion of acutely unwell psychiatric patients from all ICD-10 major diagnostic groups show
evidence of low-grade inflammation, suggesting inflammation may be relevant for all psychiatric disorders.
1. Introduction
Major psychiatric disorders such as depression, psychosis and an-
xiety are associated with low-grade systemic inflammation, as reflected
by elevated concentrations of pro-inflammatory cytokines, e.g. inter-
leukin-6, and acute phase proteins, e.g. C-reactive protein (CRP), in
peripheral blood during acute illness (Dickerson et al., 2016; Goldsmith
et al., 2016; Howren et al., 2009; Maes, 1999; Upthegrove et al., 2014;
Vogelzangs et al., 2013). Population-based longitudinal studies have
shown that elevated concentrations of inflammatory markers during
pregnancy or in childhood are associated with higher risk of developing
symptoms of depression, psychosis and mania subsequently in adult-
hood (Canetta et al., 2014; Dalman et al., 2008; Hayes et al., 2017;
Khandaker et al., 2014; Khandaker et al., 2012; Khandaker et al., 2013;
Liang and Chikritzhs, 2012; Metcalf et al., 2017), suggesting that low-
grade systemic inflammation may contribute to the development of
major psychiatric disorders. Further evidence for a role of inflammation
in psychiatric disorders comes from treatment studies. Meta-analyses of
clinical trials indicate that anti-inflammatory drugs may have anti-
depressant effects. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
and cytokine inhibitors given as adjuncts to antidepressants improve
depressive symptoms in patients with depression (Köhler et al., 2014).
Anti-cytokine drugs, which target inflammation more specifically, re-
duce the severity of depressive symptoms in patients with chronic in-
flammatory illness independently of improvements in physical illness
(Kappelmann et al., 2016). However, evidence for the efficacy of anti-
inflammatory treatment for psychotic disorders is less clear-cut. While
some studies did not find an effect (Girgis et al., 2017; Miller et al.,
2016; Nitta et al., 2013), adjunctive treatment with aspirin may be
beneficial for psychosis (Sommer et al., 2013). Minocycline, a tetra-
cyclic antibiotic, may improve negative symptoms and cognition in the
early stages of schizophrenia (Chaudhry et al., 2012; Solmi et al.,
2017).
It is likely that low-grade inflammation or anti-inflammatory drugs
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will be relevant for a subset of patients, because not all individuals with
a major psychiatric disorder show evidence of inflammation. However,
the prevalence of low-grade inflammation in patients with psychiatric
disorders and clinical characteristics of patients who show evidence of
inflammation is poorly understood. Previous studies have often com-
pared concentrations of inflammatory markers between cases and non-
cases, but there is limited data from clinical samples as to what pro-
portion of patients with different psychiatric disorders show evidence of
low-grade systemic inflammation. The proportion of depressed patients
with elevated CRP ranges from 19 to 47% according to previous studies,
but studies based on acutely unwell inpatients are scarce (Cizza et al.,
2009; Raison et al., 2013; Rethorst et al., 2014; Uher et al., 2014;
Wysokiński et al., 2015). A large, population-based study from Den-
mark reported that about one third of patients with a history of hos-
pitalisation for depression show evidence of low-grade systemic in-
flammation, defined as a serum CRP level> 3mg/L (Wium-Andersen
et al., 2013). However, data on the prevalence of inflammation in other
patient groups is limited.
A better understanding of psychiatric patients who present with
evidence of inflammation is necessary because inflammation is thought
to contribute to treatment resistance. Higher pre-treatment levels of IL-
6 predict a poorer response to antidepressants (Lanquillon et al., 2000;
Maes et al., 1997) and antipsychotics (Lin et al., 1998; Mondelli et al.,
2015) in patients with depression and schizophrenia, respectively.
Higher baseline CRP levels are associated with improvements in de-
pressive symptoms in treatment resistant depression treated with in-
fliximab, an anti-TNF-α monoclonal antibody (Raison et al., 2013).
The aims of this study were to examine the prevalence of low-grade
systemic inflammation in acutely unwell psychiatric inpatients from all
major ICD-10 diagnostic groups, and to elucidate the demographic and
clinical factors associated with inflammation in this population. We
compared psychiatric patients with and without low-grade systemic
inflammation on a number of characteristics, including socio-demo-
graphic factors, primary diagnosis, prescribed medication, medical co-
morbidity, self-harm, alcohol misuse and length of admission. We re-
peated the analyses by defining inflammation using total white cell
count (WBC) to check the robustness of associations observed using
CRP.
2. Material and methods
2.1. Setting
We carried out an anonymised search of the electronic patient re-
cords of the UK National Health Service (NHS) Cambridgeshire and
Peterborough NHS Foundation Trust (CPFT) to identify patients hos-
pitalised between 2013 and 2016 (inclusive). All patients had been
hospitalised to this mental health hospital for the treatment of a psy-
chiatric disorder. Patient records were de-identified using the Clinical
Record Interactive Search (CRIS) for secondary research (Fernandes
et al., 2013), and transferred into a research database with NHS and
institutional approvals (UK NHS National Research Ethics Service re-
ference 12/EE/0407). All patients who are admitted to CPFT acute
hospitals are offered blood testing for CRP and WBC as per hospital
protocol.
2.2. Sample selection and electronic search procedure
We searched the CRIS database for records meeting the following
inclusion criteria: a) patients admitted to inpatient beds between 2013
and 2016, inclusive; b) aged 18–65; c) had a recorded ICD-10 psy-
chiatric diagnosis (F01–F99); d) a blood test result for CRP or for WBC
had been recorded on the electronic medical notes system within
14 days of admission. Exclusion criteria were: a) patients taking anti-
biotics (proxy for a current acute infection), b) patients on oral steroids.
Patients on NSAIDs were not excluded as the presence of a chronic
inflammatory condition is a key confounder and we wanted to be able
to correct for it.
2.3. Extraction and coding of categorical information
For each patient, we extracted the following categorical information
directly from the database: date of birth/age, sex, ethnicity, marital
status, admission date, current ICD-10 diagnoses, and length of index
admission. When a patient was admitted more than once in a six-month
period, the first admission was used to avoid over-representation of
patients with recurrent admissions (see also Supplementary Figs. 1 and
2). Data extracted from CRIS included diagnostic codes which could
have been assigned to that patient at any time in the past according to
the 10th Revision of the World Health Organization International
Statistical Classification of Diseases and Related Health Problems (ICD-
10). Treating clinicians assigned the diagnoses, which were recorded by
clinicians or administrative staff.
2.4. Extraction and coding of CRP and WBC data, and definition of low-
grade inflammation
A custom-built natural language processing software was used to
extract numerical data relating to blood inflammatory markers. We
extracted all available data relating to CRP and WBC. Only entries
where CRP or WBC were recorded were kept for further analysis. The
method for data extraction was accurate and reliable as measured by
recall (probability of retrieving a record given it was relevant) and
precision (probability of a record being relevant, given it was retrieved)
statistics (see Supplementary Methods for procedure of calculating
these statistics). Blood samples from patients admitted in Cambridge or
Peterborough were tested in different labs, using assays with different
sensitivity. According to the US Centers for Disease Control and
Prevention and American Heart Association guidelines CRP levels over
3mg/L is considered to be high (Pearson et al., 2003; Ridker, 2003);
such levels are associated with increased risks of cardiovascular disease
(Koenig et al., 1999) and psychiatric illnesses such as schizophrenia
(Metcalf et al., 2017) in population-based studies. For the purpose of
this study, we have defined low-grade inflammation as a serum CRP
level> 3mg/L. This is because the hospital laboratory only reported an
exact value for CRP if it was equal or over 4mg/L; levels below this
threshold were reported as ≤3mg/L (see Supplementary Methods for
further details). Inflammation was coded as a binary variable: not in-
flamed (CRP ≤3mg/L) or inflamed ( 3mg/L). For analyses using total
WBC, we selected a cut-off value of 9.4× 109/L to define inflammation.
This cut-off represents the third quartile of the distribution of WBC in
our sample. This threshold is lower than the most common UK upper
reference value for total WBC (11× 109/L). Therefore, our approach
captured subjects with low-grade inflammation rather than those with
very high inflammation.
2.5. Data on prescribed medications including medical comorbidity
A list of medications prescribed within+/−3months of current
admission was extracted using the General Architecture for Text
Engineering (GATE) software (Cunningham et al., 2013). Medications
were manually classified in drug classes (antipsychotics, anti-
depressants, benzodiazepines and sleep inducers, mood stabilisers,
medication for medical comorbidities, NSAIDs and pain control medi-
cation, antibiotics – exclusion criterium, oral steroids – exclusion cri-
terium). Antipsychotic medications were further divided into sub-
classes (typical and atypical). Current prescriptions for an anti-hy-
pertensive, diuretic, anti-diabetic, statin, anti-aggregant, anti-coagulant
or medication for the management of dyslipidaemias were used as
proxy for the presence of common, chronic medical illness. See the
Supplementary Methods for further details about medication data
coding.
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2.6. Main psychiatric diagnosis
Many patients had more than one recorded diagnosis. We used a
hierarchical method to assign one “main diagnosis” per patient as fol-
lows: organic mental disorder> psychotic disorder>mood dis-
order> anxiety disorder> personality disorder> other psychiatric
diagnosis. Presence of a diagnosis in an earlier category trumped di-
agnosis in subsequent categories, i.e., if a patient had recorded diag-
noses of both a psychotic disorder and an anxiety disorder, psychotic
disorder was chosen as main diagnosis.
2.7. Statistical analysis
We calculated the prevalence of inflammation, defined as
CRP>3mg/L, for each major ICD-10 diagnostic group. We used lo-
gistic regression to calculate the odds ratios (ORs) and 95% confidence
intervals (CIs) for inflammation (CRP>3mg/L) for the following fac-
tors: age, sex, ethnicity, marital status, main diagnosis, self-harm, al-
cohol abuse, medical comorbidities, current medications, length of
admission. All predictors were coded as categorical variables. Age was
converted to a categorical variable using the 25th, 50th and 75th
centiles as cut-offs, which correspond to age 28, 39 and 49 years re-
spectively. Length of admission was converted to binary as above or
below median (13 days). The ORs were calculated using the following
groups as reference: female sex, white British ethnicity, single status,
age< 28, “other” diagnosis, “short” admission (< 13 days). The same
procedure was followed for analyses where inflammation was defined
as total WBC>9.4×109/L.
In addition, an independent sample t test was used to compare mean
values for continuous variables between groups with and without in-
flammation (e.g. age, length of admission); a Chi-squared test was used
for categorical variables (e.g. sex, marital status and ethnicity). We
tested the association between CRP (binary variable) and total WBC
(continuous variable) using logistic regression; high CRP (> 3mg/L)
was the dependent variable, and WBC was the independent variable. All
statistical analyses were performed in R (R Core Team, 2017). Plots
were made using ggplot2 (Wickham, 2009), using the Cairo R graphics
device (Urbanek and Horner, 2005).
3. Results
3.1. Samples
The electronic search yielded data on 6731 admissions for patients
of any age to CPFT inpatient facilities between 2013 and 2016 (in-
clusive). After applying inclusion and exclusion criteria, our analytic
sample comprised 599 admissions with data on CRP (546 unique pa-
tients). Admissions with data on WBC were 1072 (978 unique patients).
There were no differences in sex, ethnicity, or age distribution between
patients who had available blood results (analytic sample), and those
who didn’t, however the analytic sample was relatively impoverished in
married patients (see Supplementary Table 1). For CRP data, recall was
1.0 and precision was 0.96 indicating that the method for data ex-
traction was accurate and reliable. For WBC data, recall was 0.76 and
precision was 1.0. See Supplementary Figs. 1 and 2 for sample selection
methods for analysis of CRP and WBC respectively.
3.2. Prevalence of low-grade inflammation (Serum CRP level > 3mg/L)
This analysis included 599 admissions; 48% men, mean age 39 years
(SD 13). The prevalence of low-grade inflammation, as defined by
serum CRP>3mg/L, in this sample of acutely unwell, psychiatric in-
patients was 28% (see Table 1). The prevalence of inflammation in the
major ICD-10 diagnostic groups of psychotic disorders (F20–29), mood
disorders (F30–39), neurotic disorders (F40–48) and personality dis-
orders (F60–69) was 32%, 21%, 22% and 42%, respectively (see Fig. 1
and Table 3). In multivariable analyses, a diagnosis of unipolar de-
pression was associated with a decreased risk of inflammation after
adjusting for sex, age, marital status, ethnicity, main diagnosis, co-
morbidities, current medication, and length of admission (adjusted
OR=0.25; 95% CI, 0.11–0.57; p= 0.001). The other diagnoses did not
show any significant association with inflammation (see Fig. 2 and
Table 2).
3.2.1. Association with sociodemographic factors
Older age, black ethnicity and being married were associated with
inflammation, after adjusting for sex, age, marital status, ethnicity,
main diagnosis, comorbidities, current medication, and length of ad-
mission. Sex was not associated with inflammation (see Fig. 2 and
Tables 1 and 2).
3.2.2. Association with prescribed medication
Low-grade inflammation was associated with current treatments
with antidepressants (adjusted OR=1.85; 95% CI:1.03–3.33;
p=0.038), benzodiazepines and/or hypnotics (adjusted OR=1.81;
95% CI:1.01–3.22; p= 0.045). Mood stabilisers were associated with a
decreased risk of inflammation (adjusted OR=0.35; 95%
CI:0.17–0.73; p=0.005). Non-steroidal anti-inflammatory drugs and
painkillers were not associated with inflammation (see Table 2 and
Fig. 2). There was no association between the number of prescribed
psychotropic medications and the risk of inflammation. Inflammation
was not associated with antipsychotic medications after controlling for
potential confounders.
3.2.3. Association with medical comorbidity
Patients with medical comorbidities were more likely to be inflamed
(adjusted OR=2.48; 95% CI:1.20–5.13; p=0.01), after correcting for
sex, age, marital status, ethnicity, main diagnosis, other comorbidities,
current medication, and length of admission (see Table 2 and Fig. 2).
3.2.4. Association with self-harm, drug and alcohol use
Patients with a current or historical diagnosis of self-harm or poi-
soning were more likely to be inflamed compared with those without
such history (adjusted OR=1.91; 95% CI:1.12–3.25; p=0.02).
History of alcohol abuse or alcohol dependency were not associated
with inflammation (See Table 2 and Fig. 2).
3.2.5. Association with length of admission
Low-grade inflammation was not associated with total length of
admission in analyses using length of admission as a binary variable
(See Fig. 2).
3.2.6. Sensitivity analyses excluding admissions with CRP>20mg/L
In sensitivity analyses we excluded admissions of patients who
presented CRP levels> 20mg/L. The results remained mostly un-
changed (see Supplementary Fig. 3), except that the associations be-
tween inflammation and marital status and black ethnicity were no
longer statistically significant.
3.3. Results for additional analyses using high white cell count
(> 9.4×109/L) to define inflammation
3.3.1. Relationship between CRP and WBC
Data on both CRP and WBC were available for 325 participants.
Logistic regression using CRP as a binary dependent variable
(CRP>3mg/L vs ≤3mg/L) and WBC as a continuous predictor vari-
able showed that CRP was associated with WBC (beta= 0.13,
SE= 0.04, z= 3.068, p=0.002). The OR for high CRP (> 3mg/L) for
those with high WBC (> 9.4× 109/L) was 2.27 (95% CI, 1.32–3.90,
p=0.003).
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Table 1
Baseline Characteristics of Sample for CRP analyses.
Domain Characteristic Total Sample Non-Inflamed (CRP ≤3mg/
L)
Inflamed (CRP>3mg/L) Test statistic and p valuea
Sample size 599 431 (72%) 168 (28%)
Socio-demographic factors Age, mean (SD) years 39 (13) 37.5 (13) 42 (12.2) t= 4.1, df= 324, p< 0.001
Male sex, n (%) 285 (48%) 199 (46%) 86 (51%) χ2=1.02, df= 1, p= 0.31
Ethnicity, n (%) χ2=10.2, df= 4, p= 0.04
White British 441 (74%) 312 (72%) 129 (77%)
White Other 36 (6%) 31 (7%) 5 (3%)
Asian 24 (4%) 19 (5%) 5 (3%)
Black 17 (3%) 8 (2%) 9 (5%)
Other 81 (13%) 61 (14%) 20 (12%)
Marital status, n (%) χ2=9.5, df= 4, p= 0.05
Single 316 (53%) 230 (53%) 86 (51%)
Married 112 (19%) 87 (20%) 25 (15%)
Divorced 48 (8%) 26 (6%) 22 (13%)
Other 123 (21%) 88 (20%) 35 (21%)
Substance use Past/current self-harm, n (%) 135 (22.5%) 88 (20%) 47 (28%) χ2=3.5, df= 1, p= 0.06
Alcohol misuse, n (%) 118 (20%) 78 (18%) 40 (24%) χ2=2.14, df= 1, p= 0.14
Current medication Antipsychotic prescription, n (%) χ2=3, df= 3, p= 0.4
None 218 (36%) 161 (37%) 57 (34%)
Atypical 188 (31%) 137 (32%) 51 (30%)
Typical 129 (21.5%) 94 (22%) 37 (22%)
Both typical and atypical 62 (10%) 39 (9%) 23 (14%)
Antidepressant prescription 216 (36%) 152 (35%) 64 (38%) χ2=0.3, df= 1, p= 0.6
Benzodiazepine prescription 266 (44%) 184 (43%) 82 (49%) χ2=1.6, df= 1, p= 0.2
Mood stabiliser prescription 73 (12%) 56 (13%) 17 (10%) χ2=0.7, df= 1, p= 0.4
Anti-inflammatory prescriptionb 125 (21%) 89 (21%) 36 (21%) χ2=0.01, df= 1, p= 0.9
Prescriptions for medical co-morbidity 53 (9%) 31 (7%) 22 (13%) χ2=4.5, df= 1, p= 0.03
Length of admission, mean (SD) days 42 (68) 47 (73) 30 (51) t=−3, df= 403, p= 0.002
a A t test was used to compared mean values between groups (age, length of admission); a chi-squared test was used for categorical variables.
b NSAIDs and opiates.
Fig. 1. Prevalence of Inflammation (CRP>3mg/L or WBC>9.4× 109/L) by Diagnosis.
Legend: CRP: proportion of inflamed patients as measured by CRP>3mg/L; WBC: proportion of inflamed patients as measured by WBC>9.4× 109/L.
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Fig. 2. Adjusted Odds Ratios for Inflammation (CRP>3mg/L or WBC>9.4× 109/L) for Demographic and Clinical Factors.
Legend: BAD: bipolar affective disorder; PD: personality disorder; SH: self-harm.
NOTE: Reference categories are: female for sex, white for ethnicity, single for marital status, 18–27 for age, other for diagnosis, the absence of the condition for each comorbidity, and
≤13 days for length of stay. ORs are adjusted in a logistic regression model with inflammation (CRP>3mg/L) as the dependent variable, and sex, age, marital status, ethnicity, main
diagnosis, comorbidities, current medication, length of stay as predictor variables.
Table 2
Adjusted Odds Ratios for Factors Associated with Low-Grade Inflammation in Acutely Unwell Psychiatric Inpatients on Admission (CRP>3mg/L).
Characteristic Groups OR for inflammation – CRP>3mg/L (95% CI) Adjusteda OR for inflammation – CRP>3mg/L (95%
CI)
Sex Female 1.0 (reference) 1.0 (reference)
Male 1.22 (0.9–1.7) 1.06 (0.7–1.6)
Age < 28 1.0 (reference) 1.0 (reference)
28–39 2.15 (1.3–3.7) 2.36 (1.3–4.3)
40–49 2.17 (1.3–3.7) 2.86 (1.5–5.3)
> 49 2.65 (1.6–4.5) 3.01 (1.5–6.0)
Ethnicity White 1.0 (reference) 1.0 (reference)
Asian 0.69 (0.2–1.8) 0.75 (0.2–2.4)
Black 2.87 (1.1–7.9) 4.21 (1.4–12.8)
Other 0.84 (0.5–1.4) 0.79 (0.4–1.5)
Marital status Single 1.0 (reference) 1.0 (reference)
Married 0.77 (0.5–1.3) 0.49 (0.3–0.95)
Divorced 2.26 (1.2–4.2) 1.33 (0.6–2.8)
Other 1.07 (0.7–1.7) 1.07 (0.6–1.9)
Diagnosis Other (including organic brain disorders) 1.0 (reference) 1.0 (reference)
Schizophrenia 1.29 (0.7–2.3) 1.37 (0.6–3.0)
Other psychotic disorder 0.82 (0.4–1.6) 0.86 (0.4–2.0)
Bipolar mood disorder 0.99 (0.5–1.9) 1.44 (0.6–3.4)
Unipolar depression 0.45 (0.2–0.8) 0.25 (0.1–0.6)
Anxiety disorders 0.66 (0.3–1.5) 0.52 (0.2–1.5)
Personality disorders 1.68 (0.9–3.3) 1.21 (0.5–2.9)
Comorbidity Self-harm or history of self-harm 1.51 (1.0–2.3) 1.91 (1.1–3.2)
Personal history of alcohol abuse or dependency 1.42 (0.9–2.2) 1.10 (0.6–1.9)
Medication On atypical antipsychotics 1.05 (0.7–1.6) 0.52 (0.2–1.1)
On typical antipsychotics 1.11 (0.7–1.8) 0.71 (0.3–1.5)
On both typical and atypical antipsychotics 1.67 (0.9–3.0) 0.60 (0.2–1.5)
On antidepressants 1.13 (0.8–1.6) 1.85 (1.03–3.3)
On benzodiazepines 1.28 (0.9–1.8) 1.81 (1.01–3.2)
On NSAIDs and opiates 1.05 (0.7–1.6) 1.09 (0.6–1.9)
On mood stabilisers 0.76 (0.4–1.3) 0.35 (0.2–0.7)
On treatment for medical comorbidities 1.95 (1.1–3.5) 2.48 (1.2–5.1)
Length of stay in hospital above median (> 13 days) 0.74 (0.5–1.1) 0.73 (0.5–1.1)
a OR adjusted in a logistic regression model with inflammation (CRP>3mg/L) as the dependent variable, and sex, age, marital status, ethnicity, main diagnosis, comorbidities,
current medication, and length of stay as predictor variables.
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3.3.2. Prevalence of inflammation using WBC (> 9.4× 109/L)
This analysis included 1072 admissions; 56% men, mean age 39
years (SD 13). The prevalence of low-grade inflammation, defined as
WBC>9.4× 109/L, in this sample was 25% (see Supplementary
Table 2). Table 4 provides a summary of the significant findings,
comparing them to those obtained using CRP.
3.3.3. Association of high WBC (>9.4×109/L) with demographic factors
High WBC (> 9.4×109/L) was associated with married status
(adjusted OR=0.62; 95% CI:0.4–0.97; p= 0.04), older age (adjusted
OR for age 40–49, compared with age< 28=1.75; 95% CI:1.1–2.7;
p= 0.01), but not with ethnicity (see Supplementary Tables 2, 3 and
Fig. 2).
3.3.4. Association of high WBC (> 9.4× 109/L) with clinical factors
High WBC (>9.4× 109/L) was associated with a diagnosis of
schizophrenia (adjusted OR=2.41; 95% CI:1.3–4.5; p < 0.01), other
psychotic disorders (adjusted OR=1.99; CI:1.04–3.8; p= 0.04), and
bipolar affective disorder (adjusted OR=2.26; 95% CI:1.2–4.4;
p= 0.01), after adjusting the model for age, sex, ethnicity, marital
status, main diagnosis, self-harm, alcohol abuse, medical comorbidities,
current medications, length of admission. Current treatments with ty-
pical antipsychotics (adjusted OR=0.39; 95% CI:0.2–0.7; p= 0.002),
and typical plus atypical antipsychotics (adjusted OR=0.35; 95%
CI:0.2–0.7; p= 0.006) were associated with lower WBC. On the other
hand, current treatment with antidepressants (adjusted OR=1.60;
95% CI:1.04–2.4; p= 0.03) and benzodiazepines (adjusted OR=1.68;
95% CI:1.04–2.7; p= 0.04) were associated with high WBC (see Fig. 2
and Supplementary Table 3).
4. Discussion
We studied low-grade inflammation in acute psychiatric inpatients
on admission across different diagnostic groups. Overall, over a quarter
of all patients in our sample showed evidence of inflammation.
Evidence of low-grade inflammation was present in all major diagnostic
groups, with prevalences ranging from 12 to 40% depending on the
measure. A number of sociodemographic and clinical factors were as-
sociated with inflammation. Older age and current treatment with an-
tidepressants and benzodiazepines were associated with an increased
risk of inflammation after controlling for potential confounders. These
findings were consistent across analyses using CRP and WBC as markers
of inflammation. Being married appeared to be protective against in-
flammation, but evidence for this association did not persist after ex-
cluding patients with CRP>20mg/L. There was some evidence that
inflammation was associated with current/past self-harm and with
being on treatment for medical comorbidities such as diabetes, hy-
pertension and dyslipidaemia. Diagnoses of schizophrenia, other psy-
chotic disorders, and bipolar disorder were associated with an increased
risk of inflammation, while treatments with mood stabilisers or anti-
psychotics were associated decreased risk of inflammation.
There could be many reasons for a high prevalence of low-grade
inflammation in acutely unwell psychiatric patients. Psychological
stress can activate the immune system (Padgett and Glaser, 2003).
Exposure to early-life adversity, common in psychiatric patients, can
increase levels of inflammation in adulthood (Baumeister et al., 2016).
Inflammation could be a marker of co-morbid inflammatory physical
illness. However, accumulating evidence suggests that inflammation
could be an intrinsic part of psychiatric illnesses. Meta-analyses of
cross-sectional studies show increased levels of inflammatory markers
Table 3
Number and Characteristics of Psychiatric Inpatients by Diagnosis.
Diagnosis Total n Age, Mean (SD)
Years
Male Sex, n
(%)
White British ethnicity, n
(%)
N with CRP
data
Inflammation (CRP>3mg/L), n
(%)
F00-F09 Organic Mental Disorders 17 52 (12) 8 (47%) 13 (77%) 8 1 (13%)
F20-F29 Psychotic Disorders 445 40 (12) 284 (64%) 275 (62%) 185 59 (32%)
F20 Schizophrenia 232 40 (11) 165 (71%) 150 (65%) 112 40 (36%)
F21-29 Other Psychoses 213 40 (13) 119 (56%) 125 (59%) 73 19 (26%)
F30-F39 Mood Disorders 523 41 (13) 245 (47%) 381 (73%) 211 44 (21%)
F30-31 Bipolar 191 44 (13) 87 (46%) 134 (70%) 74 22 (30%)
F32-39 Unipolar or Unspecified 332 40 (13) 158 (48%) 247 (74%) 137 22 (16%)
F40-F48 Neurotic, stress- related and
somatoform dis.
131 34 (11) 69 (53%) 102 (78%) 41 9 (22%)
F60-F69 Personality Disorders 149 33 (10) 51 (34%) 121 (81%) 62 26 (42%)
Other F diagnoses 188 39 (13) 122 (65%) 139 (74%) 92 29 (32%)
Table 4
Summary of significant findings.
OR for inflammation defined as
CRP>3mg/L
OR for inflammation defined as
WBC>9.4*109/L
Concordance between CRP and WBC
analyses
Black ethnicity ↑ ⇣ N
Married status ↓ ↓ ↓
Older age ↑ ↑ ↑
Diagnosis of schizophrenia ⇡ ↑ ⇡
Diagnosis of bipolar disorder ⇡ ↑ ⇡
Diagnosis of unipolar depression ↓ ⇡ N
Current or past self-harm ↑ ↔ N
Current treatment with typical or atypical
antipsychotics
⇣ ↓ ⇣
Current treatment with antidepressants ↑ ↑ ↑
Current treatment with benzodiazepines ↑ ↑ ↑
Current treatment with mood stabilisers ↓ ⇡ N
Current treatment for medical comorbidity ↑ ↔ N
Legend: ↑=OR>1 and statistically significant suggesting these factors increase inflammation; ↓=OR<1 and statistically significant suggesting these factors decrease inflammation;
⇡=OR>1 but not statistically significant suggesting these factors may decrease inflammation; ⇣=OR<1 but not statistically significant suggesting these factors may decrease
inflammation; ↔=OR not statistically different from 1; N= results are not concordant between CRP and WBC.
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in acutely unwell patients with depression and psychosis (Howren
et al., 2009; Potvin et al., 2008). Population-based longitudinal studies
have reported that higher levels of IL-6 and CRP are associated with
symptoms/diagnosis of depression, mania and psychosis subsequently
in life (Gimeno et al., 2009; Hayes et al., 2017; Khandaker et al., 2014;
Khandaker et al., 2017; Metcalf et al., 2017; Zalli et al., 2016), sug-
gesting low-grade inflammation could be a cause for these illnesses,
rather than simply being a consequence.
Our results are in line with previous studies reporting prevalence of
low-grade inflammation (CRP>3mg/L) in depression (Cizza et al.,
2009; Raison et al., 2013; Wium-Andersen et al., 2013). These studies
have investigated inflammation in depression in specific contexts such
as in premenopausal women, in depressed outpatients, or in the general
population. Our study adds to previous findings by reporting the pre-
valence of inflammation a) in a psychiatric inpatient population, and b)
in other patient groups.
A previous study examined the prevalence of inflammation in the
general population, and found that, using reference limits set at the
time of the analysis, for WBC 21.4% of the population had an above-
reference value, and for CRP 22.2% of the population had above-re-
ference results (Andersen et al., 2014). However, it should be noted that
cut-offs for WBC/CRP levels used to define low-grade inflammation in
our study were different, as we were interested in low-grade in-
flammation.
Associations of inflammation with older age, marital status and
ethnic minority status are consistent with previous studies (Khera et al.,
2005; Sbarra, 2009; Wener et al., 2000; Woloshin and Schwartz, 2005),
although we have not seen any association with sex. In our sample,
current treatments with antidepressants, anxiolytics/hypnotics were
robustly associated with inflammation. This is consistent with previous
studies reporting elevated levels of inflammatory markers in patients
with depression (Dowlati et al., 2010; Goldsmith et al., 2016;
Haapakoski et al., 2015; Howren et al., 2009). Furthermore, raised le-
vels of the inflammatory cytokine IL-6 in childhood are associated with
an increased risk of developing depression and psychosis in young
adulthood (Khandaker et al., 2014), and persistent depressive symp-
toms during the second decade of life (Khandaker et al., 2017). How-
ever, a diagnosis of depression was associated with lower risk of in-
flammation, which is surprising. It is possible that antidepressant
prescription is a better proxy for current depression in our sample; data
on diagnoses obtained from electronic health records were historical,
while prescription data refers to the current admission. Nevertheless,
there was some evidence that high WBC was associated with a diagnosis
of depression although this was not statistically significant. We did not
have repeat measures of CRP/WBC at the end of the admission, so it
was not possible to examine the association of inflammation with
treatment response.
Association of inflammation with self-harm and medical co-
morbidities are consistent with previous studies. Previous studies have
reported an association between inflammation and suicidal ideation/
behaviour (Gibbs et al., 2016; Park and Kim, 2017). Self-harm and
suicidal ideas are markers of psychiatric multi-morbidity (Hui et al.,
2013), so reflect patients with greater psychological distress. Previous
studies have reported that inflammatory markers are associated with
the severity of depressive symptoms (Köhler-Forsberg et al., 2017) and
with persistent depressive symptoms (Khandaker et al., 2017; Zalli
et al., 2016). Both cardiovascular disease and diabetes mellitus are
associated with low-grade inflammation (Koenig et al., 1999; Pearson
et al., 2003). There is evidence of insufficient glucocorticoid signalling
and elevated inflammation in coronary heart disease patients with co-
morbid depression (Nikkheslat et al., 2015). However, data on medical
comorbidities were often missing in the electronic health record, so
prescribed medications were used as a proxy.
A decreased risk of inflammation in patients taking mood stabilisers
is consistent with known anti-inflammatory effects of lithium (Kucharz
et al., 1993; Sluzewska et al., 1997) and valproate (Yuen et al., 2010).
CRP levels increase during a manic phase, which is at least partially
reversed by treatment with mood stabilisers (Fernandes et al., 2016).
Our finding is also consistent with a previous longitudinal study re-
porting an association between childhood IL-6 levels and lifetime hy-
pomanic symptoms assessed in adulthood (Hayes et al., 2017). Inter-
estingly, inflammation was not associated with the prescription of
NSAIDs, which was used as a proxy for chronic inflammatory illness.
This suggests that the inflammation seen in psychiatric patients in our
sample might not be driven solely by co-morbid inflammatory medical
conditions, but it could rather be inherent to their psychiatric illness.
The diagnoses of schizophrenia and bipolar affective disorder were
also associated with an increased risk of inflammation measured
through WBC, while antipsychotic treatment was associated with a
protective effect. The results are consistent with recent evidence
showing there is an increase in peripheral inflammatory markers in
schizophrenia, which normalised with antipsychotic treatment. IL-1β,
IL-6, and transforming growth factor-β (TGF-β) are schizophrenia state
markers, as they increase in acute relapses and first episode psychosis
and normalize with antipsychotic treatment (Miller et al., 2011). In
contrast, IL-12, IFN-γ, TNF-α, and soluble IL-2 receptor are trait mar-
kers, as levels remain elevated in acute exacerbations and following
antipsychotic treatment. Furthermore, IL-6 levels correlate positively
with symptom severity (Miller et al., 2011). There is evidence that
elevated CRP in adolescence is associated with increased risk of psy-
chosis later on in life (Metcalf et al., 2017).
The limitations of this study need to be considered carefully. This
study is based on retrospective analysis of data from an electronic
health record that was not created for the purpose of research. Although
the work demonstrates that routine clinical databases can be used to
address important research questions, there are limitations to using
routine clinical data. Missing data is a key issue. Although all patients
admitted to CPFT inpatient hospitals are offered a physical examination
including a blood test (which includes WBC and CRP routinely), only a
subset of all potentially eligible patients had data on inflammatory
markers. Approximately 41% of the admissions that we considered
(Supplementary Figs. 1 and 2) had recorded blood results within
14 days of admission. The remaining 59% who did not have blood re-
sults recorded within 2 weeks of admission were not included in our
study; these patients might have refused venepuncture at the time of
admission or had bloods taken after 14 days of coming into hospital,
which we excluded from our study to minimize potential effects of
hospital treatment. CRP and WBC data recall and precision also affected
the probability of inclusion into the analytic sample, as described in the
methods. While the possibility of selection bias due to missing data
cannot be ruled out, it is unlikely that blood tests were offered primarily
because of a suspected physical illness. Therefore, the increased pre-
valence of inflammation in psychiatric patients is unlikely to be due to a
physical illness. Data on diagnosis were also missing for many patients.
We included only patients with a clinician-coded ICD-10 diagnosis to
increase accuracy. Therefore, diagnosis data are more specific than
sensitive. However, patients often more than one psychiatric diagnosis,
so we used a hierarchical approach to assign a single main diagnosis to
each patient. This hierarchical approach has been used previously in
psychiatric research (Foulds and Bedford, 1975). It is possible that for
some patients the reason for admission was different from their main
diagnosis, leading to misclassification of diagnosis. However, this is
unlikely to be an issue for a majority of patients.
To explore potential selection bias due to missing data, we com-
pared demographic factors between the analytic sample and missing
sample (all unique patients meeting all selection criteria but with no
recorded CRP on admission). These samples were similar in terms of
sociodemographic factors except for marital status, suggesting that,
while the possibility of selection bias cannot be ruled out, it is unlikely
to be a major issue (see Supplementary Table 1). However, the pre-
valence of inflammation in patients with depression observed in our
sample is comparable to previous studies of depression (Cizza et al.,
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2009; Raison et al., 2013; Wium-Andersen et al., 2013): this is re-
assuring. The database would not differentiate between first and sub-
sequent admissions for a specific patient for a given diagnosis, therefore
we were unable to compare recent onset cases with those with chronic
illness.
A recent clinical study found associations between WBC and greater
bipolar severity (Köhler et al., 2017). We did not have data on severity
of illness. However, the fact that patients were admitted to hospital is
an indication that they were severely unwell.
Our study is limited to patients who were admitted to hospital. To
our knowledge, this is one of the first studies to examine the prevalence
of inflammation in psychiatric inpatients from all major ICD-10 diag-
nostic groups. However, the decision to admit is often guided by clinical
risk perceived by clinicians, so the findings may not be generalizable to
all patients. We did not have readily available data on BMI, smoking or
recreational drug use. Therefore, the association between inflammation
and diagnosis of psychosis might reflect antipsychotic induced obesity/
metabolic disturbance. Due to the lack of an electronic prescribing
system, we used a natural language processing software to extract
names of prescribed drugs from medical notes. This system has been
previously validated in a similar study (Cardinal et al., 2015). However,
while we were able to ascertain whether a particular drug was pre-
scribed or not, we could not ascertain specific indication for that pre-
scription. The same psychotropic drugs can be prescribed for many
disorders. Therefore, the relationship between prescribed anti-
depressant and inflammation might reflect that inflammation is asso-
ciated with a range of disorders for which these drugs are prescribed,
rather than depression specifically.
5. Conclusions
In summary, our findings indicate that a large minority of acutely
unwell psychiatric patients show evidence of low-grade systemic in-
flammation, regardless of their diagnosis. Low-grade inflammation is
associated with a number of socio-demographic and clinical factors,
which may help to characterise an inflammatory sub-type of the major
psychiatric disorders. For conditions such as depression, it is known
that an inflammatory phenotype is associated with treatment re-
sistance. This is not known for all other psychiatric disorders.
Characterising the inflammatory sub-type of psychiatric disorders could
therefore allow to predict which patients might be treatment resistant,
and incentivises work into elucidating the clinical phenotype of in-
flamed patients presenting with other psychiatric conditions.
However, before our work can be generalised further work based on
other settings (e.g., outpatients) and samples (e.g., general population)
is required.
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